Advertisement
Advertisement

VNDA

VNDA logo

Vanda Pharmaceuticals Inc.

7.56
USD
Sponsored
+0.56
+8.00%
May 04, 16:00 UTC -4
Closed
exchange

After-Market

7.54

-0.02
-0.33%

Vanda Pharmaceuticals Inc. Profile

About

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial.

Info & Links

CEO

Mihael H. Polymeropoulos

Headquarters

2200 PENNSYLVANIA AVENUE NW, SUITE 300E
WASHINGTON, DC 20037, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.vandapharma.com

Auditor

PricewaterhouseCoopers LLP

Share holders

10

Employees

533

Vanda Pharmaceuticals Inc. Statistics

Valuation Measures

Market Capitalization2

453.12M

Enterprise Value

372.34M

Enterprise Value/EBITDA(ttm)

-2.64

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

2.00

Price to Book(mrq)

1.32

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

93.95%

Operating Margin(ttm)

-49.41%

Profit Margin(ttm)

-99.40%

Return on Equity(ttm)

-23.85%

Return on Invested Capital(ttm)

-58.73%

Return on Assets(ttm)

-18.20%

Income Statement

Revenue(ttm)

216.11M

Revenue Per Share(ttm)

3.66

Gross Profit(ttm)

203.06M

EBITDA(ttm)3

-141.30M

Net Income Available to Common(ttm)

-220.47M

Diluted EPS(ttm)

-3.73

Share Statistics

Beta (5Y Monthly)

0.71

52-Week Change

65.43%

S&P 500 52-Week Change

27.44%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

59.11M

Dividend Yield

0.00%

Float4

53.20M

% Held by Insiders

10.00%

% Held by Institutions

88.14%

Balance Sheet

Total Cash(mrq)

263.85M

Total Cash Per Share(mrq)

4.46

Total Debt(mrq)

4.08M

Total Debt/Equity(mrq)

1.25%

Current Ratio(mrq)

2.39%

Quick Ratio(mrq)

2.38%

Book Value Per Share(mrq)

5.54

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.86

Free Cash Flow(ytd)

-110.44M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement